E-LIB Suche - Ergebnisse für: Montastruc, Guillaume

1

Valvular heart disease in a patient taking 3,4‐methylenedio..:

Montastruc, François ; Montastruc, Guillaume ; Vigreux, Philippe...
British Journal of Clinical Pharmacology. 74 (2012) 3 - p. 547-548 , 2012

Link: https://doi.org/10.1111/..

2

Drugs and dilated cardiomyopathies: a case/noncase study in..:

Montastruc, Guillaume ; Favreliere, Sylvie ; Sommet, Agnès...
British Journal of Clinical Pharmacology. 69 (2010) 3 - p. 287-294 , 2010

Link: https://doi.org/10.1111/..

3

Cardiovascular safety of methylphenidate should also be con..:

Montastruc, François ; Montastruc, Guillaume ; Montastruc, Jean-Louis.
BMJ: British Medical Journal. ,

Link: https://www.jstor.org/st..

4

Valvular heart disease in a patient taking 3,4-methylenedio..:

Montastruc, François ; Montastruc, Guillaume ; Vigreux, Philippe...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477357. , 2012

Link: http://www.ncbi.nlm.nih...

5

Drugs and dilated cardiomyopathies: a case/noncase study in..:

Montastruc, Guillaume ; Favreliere, Sylvie ; Sommet, Agnès...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2829699. , 2010

Link: http://www.ncbi.nlm.nih...

6

Gingival bleeding, a possible "serious" adverse drug reacti..:

Bondon‐Guitton, Emmanuelle ; Mourgues, Thibaut ; Rousseau, Vanessa...
Journal of Clinical Periodontology. 44 (2017) 9 - p. 898-904 , 2017

Link: https://doi.org/10.1111/..

7

Risk of thrombosis in patients with primary immune thromboc..:

Moulis, Guillaume ; Audemard-Verger, Alexandra ; Arnaud, Laurent...
Autoimmunity Reviews. 15 (2016) 3 - p. 203-209 , 2016

Link: https://doi.org/10.1016/..

8

Need for an improved vaccination rate in primary immune thr..:

Moulis, Guillaume ; Lapeyre‐Mestre, Maryse ; Mahévas, Matthieu..
American Journal of Hematology. 90 (2015) 4 - p. 301-305 , 2015

Link: https://doi.org/10.1002/..

9

Exposure to non-corticosteroid treatments in adult primary ..:

Moulis, Guillaume ; Lapeyre-Mestre, Maryse ; Montastruc, Jean-Louis.
Autoimmunity Reviews. 14 (2015) 2 - p. 168-173 , 2015

Link: https://doi.org/10.1016/..

10

Tumor necrosis factor inhibitors added to nonbiological imm..:

Saliba, Layla ; Moulis, Guillaume ; Abou Taam, Malak...
Fundamental & Clinical Pharmacology. 30 (2015) 2 - p. 162-171 , 2015

Link: https://doi.org/10.1111/..

11

Signal for Thrombosis with Eltrombopag and Romiplostim: A D..:

Nguyen, Thi-Thanh Loan ; Palmaro, Aurore ; Montastruc, François..
Drug Safety. 38 (2015) 12 - p. 1179-1186 , 2015

Link: https://doi.org/10.1007/..

12

Are adverse drug reaction patterns different between romipl..:

Moulis, Guillaume ; Bagheri, Haleh ; Sailler, Laurent...
European Journal of Internal Medicine. 25 (2014) 8 - p. 777-780 , 2014

Link: https://doi.org/10.1016/..

13

Interactions between Medical Residents and Drug Companies: ..:

Montastruc, François ; Moulis, Guillaume ; Palmaro, Aurore...
PLoS ONE. 9 (2014) 10 - p. e104828 , 2014

Link: https://doi.org/10.1371/..

14

Is the risk of tumour necrosis factor inhibitor-induced lup..:

Moulis, Guillaume ; Sommet, Agnès ; Lapeyre-Mestre, Maryse.
Rheumatology. 53 (2014) 10 - p. 1864-1871 , 2014

Link: https://doi.org/10.1093/..

15

Reply to the commentary by Onuigbo on the article "Exposure..:

Moulis, Guillaume ; Sailler, Laurent ; Montastruc, Jean‐Louis
Pharmacoepidemiology and Drug Safety. 21 (2012) 8 - p. 900-901 , 2012

Link: https://doi.org/10.1002/..